Peter Meijer sold Abbott Laboratories (NYSE: ABT)
Peter Meijer (R-MI), a U.S. Representative, has disclosed 1 trade in Abbott Laboratories (ABT) since 2021, a single sale, worth an estimated $33K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Peter Meijer sold $15,001 - $50,000 of Abbott Laboratories (NYSE: ABT) on February 16, 2021. Since that trade, ABT is down -9.04% against the S&P 500 up +103.09%, an outperformance of -112.14%.
Data updated
Peter Meijer's ABT trades vs the price
ABT is down -9.04% since Peter Meijer sold on February 16, 2021, versus +103.09% for the S&P 500.
Performance since this trade
All Peter Meijer ABT trades
Peter Meijer & ABT trading FAQ
Is it legal for Peter Meijer to trade Abbott Laboratories (ABT) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Abbott Laboratories (ABT), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Peter Meijer sell ABT?
Peter Meijer disclosed a sale of $15,001 - $50,000 of Abbott Laboratories (ABT) on February 16, 2021, according to public STOCK Act filings.
How has ABT performed since Peter Meijer's trade?
Since Peter Meijer sold ABT on February 16, 2021, the stock is down -9.04%, versus +103.09% for the S&P 500 over the same period, an outperformance of -112.14%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional ABT trades?
Quantellect tracks every disclosed congressional trade in Abbott Laboratories (ABT) on the Abbott Laboratories congressional trading page, which aggregates filings across all members of Congress.
Peter Meijer's ABT tradesAll congressional filings for Abbott LaboratoriesPeter Meijer's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.